|
Gallbladder volume, cc (95% CI)
|
n = 23
|
n = 11
|
n = 11
|
|
Baseline
|
33.3 (22.5–44.1)
|
48.1 (23.1–73.1)
|
40.2 (14.1–66.2)
|
|
Mean change from baseline
|
17.7 (6.4–28.9)
|
26.8 (11.5–42.1)
|
26.9 (8.8–45.1)
|
|
Maximum change from baseline
|
45.6 (20.2–70.9)
|
74.4 (41.3–107.4)
|
67.3 (30.8–103.8)
|
|
Gallbladder ejection fraction, % (95% CI)
|
n = 21
|
n = 10
|
n = 10
|
|
Baseline
|
59.1 (43.5–74.8)
|
68.7 (50.5–87.0)
|
58.5 (38.4–78.6)
|
|
Mean change from baseline
|
−24.1 (−38.2 to −9.9)
|
−25.0 (−43.9 to −6.1)
|
−3.3 (−25.0 to 18.4)
|
|
Maximum change from baseline
|
−30.1 (−46.4 to −13.7)
|
−26.5 (−45.0 to −8.0)
|
−6.5 (−29.8 to 16.8)
|
|
Reversibility of gallbladder volume changes, cc (95% CI)
|
n = 16
|
n = 9
|
n = 8
|
|
Mean change in gallbladder volume after discontinuation of motesanib
|
−8.5 (−38.8 to 21.7)
|
−16.2 (−37.4 to 5.1)
|
−7.4 (−67.1 to 52.4)
|
|
Mean change in gallbladder volume from baseline to last available off- treatment measurement
|
10.4 (−10.0 to 30.8)
|
−14.4 (−31.1 to 2.4)
|
7.1 (−28.9 to 43.0)
|
|
Reversibility of gallbladder ejection fraction changes, % (95% CI)
|
n = 5
|
n = 3
|
n = 2
|
|
Mean change in ejection fraction after discontinuation of motesanib
|
10.8 (−45.8 to 67.4)
|
63.0 (24.0 to 102.0)
|
46.0 (−347.9 to 439.9)
|
|
Mean change in ejection fraction from baseline to last available off- treatment measurement
|
−16.6 (−53.3 to 20.1)
|
7.7 (−3.8 to 19.1)
|
14.5 (−55.4 to 84.4)
|
